Description: Hemostemix is a clinical-stage biotechnology company focused on developing and commercializing a proprietary autologous cell therapy to treat ischemic diseases.
Hemostemix is an autologous (patient’s own) stem cell therapeutics company that holds 87 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01 have been used as a treatment of 500 subjects, studied in including clinical trials, and are demonstrated to be completely safe and effective as a treatment of Angina, Dilated and Ischemic Cardiomyopathy , Peripheral Arterial Di
Drawn from your blood, differentiated into ACP-01 and reintroduced into your heart by your physician seven days later,for example, ACP-01 forms new circulation where the body signals it needs regeneration. It’s why we globally trademarked “Your Fountain of Youth!”
Hemostemix Inc. has two wholly owned subsidiaries, Kwalata Trading Limited (IP Hold Co.) and PreCerv Inc. PreCerv holds a global field of use license to ACP-01 & NCP-01 for the treatment of conditions of the central and peripheral nervous system.